Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide Alone or With Mifepristone vs Chemotherapy in AR+ Metastatic TNBC or ER-Low Breast Cancer
NCT06099769Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2023
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enzalutamide in breast cancer and triple-negative breast cancer (TNBC) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 2 years. Started Oct 2023; status: recruiting.
02
Drugs
enzalutamide
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06099769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099769.